Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results
May 09, 2018 07:30 ET
|
Paratek Pharmaceuticals
-- New drug applications for omadacycline accepted for priority review by FDA; PDUFA action date in October 2018 -- -- Company on track for a first quarter 2019 omadacycline U.S. launch -- --...
Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 01, 2018 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, May 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018
April 25, 2018 17:03 ET
|
Paratek Pharmaceuticals
BOSTON, April 25, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID
April 23, 2018 07:30 ET
|
Paratek Pharmaceuticals
Company on track to file marketing authorization applications in the European Union in the second half of 2018 Data on utility in geographic regions also presented MADRID, Spain, April 23, 2018 ...
Paratek Pharmaceuticals Presents New Microbiology Efficacy Data of Oral-only Omadacycline Against the Most Common Pathogens Associated with Skin Infections
April 23, 2018 07:30 ET
|
Paratek Pharmaceuticals
- First presentation of the OASIS-2 topline results - Sub-analysis examining efficacy of oral-only omadacycline on lesion size also presented at ECCMID 2018 MADRID, Spain, April 23, 2018 (GLOBE...
Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024
April 19, 2018 08:45 ET
|
Paratek Pharmaceuticals
BOSTON, April 19, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024
April 18, 2018 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, April 18, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Appoints Rolf K. Hoffman to Company’s Board of Directors
April 13, 2018 16:40 ET
|
Paratek Pharmaceuticals
-- Led U.S. and International Commercial Operations at Amgen Inc.-- BOSTON, April 13, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on...
Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018
April 12, 2018 07:30 ET
|
Paratek Pharmaceuticals
- First oral presentation of the results of OASIS-2, the Phase 3 omadacycline oral-only study in ABSSSI - Poster presentations include new microbiology analyses from OASIS-2 BOSTON, April 12, 2018 ...
Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
April 04, 2018 16:01 ET
|
Paratek Pharmaceuticals
-- PDUFA Action Date in October 2018 -- BOSTON, April 04, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that the U.S. Food and Drug Administration (FDA) has...